ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1189

Stromal Cell Markers in the Synovial Tissue of Patients with Early Arthritis and Preclinical Rheumatoid Arthritis

Yuen Kei Choi1, Olga N. Karpus2, Paul Peter Tak3, Jörg Hamann4, Christopher D. Buckley5, Andrew Filer6 and Danielle M. Gerlag7, 1Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 21Departments of Experimental Immunology and Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, 3Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, 4Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 5Center for Translational Inflammation Research, School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom, 6Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 7Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: diagnosis, prognostic factors, rheumatic disease and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

 

Background/Purpose:

Stromal cells in synovial tissue (ST) of patients with arthritis may have an important role in the initiation and persistence of the inflammatory infiltrate. Previous studies showed increased expression of stromal markers in ST of patients with established rheumatoid arthritis (RA) (Maia et al, Arthritis Rheum 2010:62:3595; Ekwall et al, Arthritis Res Ther 2011:13:R40). Here we investigated the expression of CD248, gp38, CD55 and PDI in early arthritis in relationship to diagnosis and outcome. Furthermore, these markers were tested in the ST of individuals without clinically apparent arthritis who are at risk for developing RA.

 

Methods:

Forty-seven patients with early inflammatory arthritis (<1 year disease duration) and 19 IgM rheumatoid factor and/or anti-citrullinated peptide antibody (ACPA) positive individuals with arthralgia but without arthritis were included in this study. Of the latter group, 9 individuals developed arthritis after a mean follow-up time of 3.4 years. In the early arthritis cohort, patients were diagnosed at baseline and at 2 years follow up as gout (n = 10), psoriatic arthritis (PsA, n = 9), undifferentiated arthritis (UA-UA, n = 10), UA-RA (n = 4) and RA-RA (n = 14). Patients were also classified based on prognostic outcome after 2 years into self-limiting, persistent non-erosive and persistent erosive disease. Synovial tissue was obtained by miniarthroscopy and analyzed by immunofluorescence to detect CD248, gp38, CD55 and PDI on stromal cells.Slides were examined by confocal microscopy. Expression was quantified as pixel/um². Kruskal–Wallis test and Mann–Whitney U test were used for statistical analysis. A P-value <0.05 was considered statistically significant.

 

Results:

We observed clear expression of CD248, gp38, CD55 and PDI in ST of patients with early arthritis, independent of diagnosis or outcome (table 1). In the autoantibody positive subjects at risk of developing RA, the expression of gp38 was lower compared to early RA (p = 0.0025). Expression levels were not different between individuals who developed RA after follow up (n = 9) compared to those who did not (n = 10).

 

Conclusion:

The stromal cell markers CD248, gp38, PDI and CD55 are all expressed in the earliest stages of clinically manifest arthritis, independent of the diagnosis and outcome after follow up. In preclinical RA the expression of gp38 is lower compared to early RA. Stromal markers seem to be expressed in a stable way in the ST during the development from being at risk of RA to early RA.

 

Table 1. Median expression levels in early arthritis and preclinical RA

Median expression

Expression levels in early arthritis in reationship to diagnosis

Expression levels in early arthritis in relationship to outcome

Expression levels in preclinical RA

(in pixel/um²)

Gout

PsA

RA-RA

UA-RA

UA-UA

P*

Erosive

Non-erosive

Self limiting

P*

Arthritis+

Arthritis-

P*

CD248

0.037

0.056

0.026

0.080

0.043

ns

0.018

0.026

0.053

ns

0.015

0.051

ns

Gp38

0.007

0.030

0.008

0.003

0.009

ns

0.010

0.008

0.005

ns

0.000

0.000

ns

CD55

0.014

0.027

0.014

0.017

0.006

ns

0.016

0.011

0.016

ns

0.017

0.019

ns

PDI

0.056

0.075

0.026

0.022

0.037

ns

0.025

0.044

0.037

ns

0.004

0.004

ns

*ns: not significant, p-value ≥0.05

Arthritis +: Seropositive individuals who developed arthritis during follow-up time of 3.4 years

Arthritis -: Seropositive individuals who did not develop arthritis after a mean follow-up time of 3.4 years

 

 


Disclosure:

Y. K. Choi,
None;

O. N. Karpus,
None;

P. P. Tak,

Employee of GlaxoSmithKline,

3;

J. Hamann,
None;

C. D. Buckley,
None;

A. Filer,
None;

D. M. Gerlag,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stromal-cell-markers-in-the-synovial-tissue-of-patients-with-early-arthritis-and-preclinical-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.